|1.||Fujiwara, T: 2 articles (10/2000 - 01/2000)|
|2.||Sugimoto, H: 2 articles (10/2000 - 01/2000)|
|3.||Hattori, N: 2 articles (10/2000 - 01/2000)|
|4.||Yoshimoto, J: 2 articles (10/2000 - 01/2000)|
|5.||Hsieh, Hsing-Pang: 1 article (01/2007)|
|6.||Hsu, John T-A: 1 article (01/2007)|
|7.||Ono, J: 1 article (10/2000)|
|8.||Sugita, K: 1 article (10/2000)|
|9.||Yagi, S: 1 article (10/2000)|
|10.||Hashimoto, N: 1 article (10/2000)|
|1.||Human Influenza (Influenza)
10/01/2000 - "Development of anti-influenza drugs: II. Improvement of oral and intranasal absorption and the anti-influenza activity of stachyflin derivatives."
01/01/2000 - "Stachyflin-resistant variants of human influenza A/WSN/33 (H1N1) virus were isolated in vitro and the nucleotide sequences of their HA genes were determined. "
07/01/1999 - "Development of anti-influenza virus drugs I: improvement of oral absorption and in vivo anti-influenza activity of Stachyflin and its derivatives."
01/01/1999 - "Stachyflin has no inhibition on H3 subtype influenza A or influenza B viruses. "
01/01/2000 - "We have recently described a novel hemagglutinin (HA) conformational change inhibitor of human influenza virus, Stachyflin (Yoshimoto et al, Arch. "
01/01/1999 - "The results of the timing of Stachyflin addition against in vitro virus infection and virus-mediated hemolysis assay suggested that the drug inhibited the HA-mediated virus-cell fusion process. "
01/01/2007 - "For instance, included are descriptions of (1) inhibitors of HA cleavage, such as nafamostat, camostat, gabexate, epsilon-aminocapronic acid and aprotinin, (2) inhibitors of fusion and entry, such as benzoquinones and hydroquinones, CL 385319, BMY-27709, stachyflin, and their analogues, (3) inhibitors of viral RNPs/polymerase/endonuclease, such as T-705, L-735,822, flutimide and their analogues, (4) inhibitors of MEK, such as PD 0325901, CI-1040 and ARRY-142886, and (5) inhibitors of NA such as DANA, FANA, zanamivir, and oseltamivir, etc. Although amantadine and rimantadine are not recommended for treating influenza virus infections because of drug resistance problem, these viral M2 ion channel blockers established a proof-of-concept that the endocytosis of virion into host cells can be a valid drug target because M2 protein is involved in the endocytosis process. "
|7.||Ion Channels (Ion Channel)